Prosecution Insights
Last updated: October 25, 2026
Application No. 18/343,523

MEAT SUBSTITUTE COMPRISING ANIMAL MYOGLOBIN

Non-Final OA §102
Filed
Jun 28, 2023
Priority
Dec 31, 2020 — EU 20218000.6 +3 more
Examiner
STULII, VERA
Art Unit
1791
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Paleo B V
OA Round
1 (Non-Final)
33%
Grant Probability
At Risk
1-2
OA Rounds
11m
Est. Remaining
58%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
285 granted / 871 resolved
-32.3% vs TC avg
Strong +25% interview lift
Without
With
+24.9%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
55 currently pending
Career history
922
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
61.3%
+21.3% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
18.7%
-21.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 871 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Election/Restrictions Claims 7-23 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 05/20/2026. Applicant's election with traverse of claims 1-6 and 24 in the reply filed on 05/20/2026 is acknowledged. The traversal is on the ground(s) that it would not be an undue burden for Examiner to search groups II-VII. This is not found persuasive because all the inventions of Groups I-VII are independent or distinct for the reasons given in the Election/Restriction requirement mailed 03/24/2026 and there would be a serious search and/or examination burden if restriction were not required because one or more of the following reasons apply: The inventions have acquired a separate status in the art in view of their different classification. The inventions have acquired a separate status in the art due to their recognized divergent subject matter. The inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries). The prior art applicable to one invention would not likely be applicable to another invention. The inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph. Applicant’s election of myoglobin of mammoth and SEQ ID NO:3 species is acknowledged. The requirement is still deemed proper and is therefore made FINAL. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-6 and 24 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Fraser et al (WO 2015/038796 A2). In regard to claim 1-4 and 24, Fraser et al discloses meat substitute comprising a recombinantly expressed polypeptide such as myoglobin where sequence IDs Nos 18-21 identical or very similar to Seq ID No 3 as claimed (amino acid sequence of steppe mammoth myoglobin) ([0045], [0176], [0181], [0186], [0252]). In regard to claim 5-6, Fraser et al discloses: [0181] The disclosure provides for methods for the use of a polypeptide of the disclosure in a meat consumable. The consumables can compete with, supplement or replace animal based foods. For instance the consumables can be meat replicas made entirely from plant sources. The consumables can be made to mimic the cut or appearance of meat as it is currently sold. For instance a consumable may be visually similar to or indistinguishable from ground beef or a particular cut of beef. Alternatively, the consumables can be made with a unique look or appearance. For instance the consumable could contain patterns or lettering that is based upon the structure of the consumable. In some instances the consumables can look like traditional meat products after they are prepared. For example a consumable may be produced which is larger than a traditional cut of beef but which, after the consumable is sliced and cooked appears the same as a traditional cooked meat. In some embodiments the consumable may resemble a traditional meat shape in two dimensions, but not in a third. For example the consumable may resemble a cut of meat in two dimensions (for example when viewed from the top), but may be much longer (or thicker) than the traditional cut. A meat consumable (e.g., substitute) can have similar physical characteristics as traditional meat (taste, texture, force, nutrients). In some embodiments, a meat consumable can comprise a similar cook loss characteristic as meat. In some embodiments a meat consumable can comprise a similar fat and protein content as ground beef has the same reduction in size when cooked as real ground beef. Methods of producing a meat consumable are described in PCT/US2012/046560, which is hereby incorporated by reference in its entirety. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to VERA STULII whose telephone number is (571)272-3221. The examiner can normally be reached Monday-Friday 5:30AM-3:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Nikki Dees can be reached at 571-270-3435. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /VERA STULII/Primary Examiner, Art Unit 1791
Read full office action

Prosecution Timeline

Jun 28, 2023
Application Filed
Oct 01, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12765569
FOOD PRODUCTS AND SYSTEMS AND METHODS OF MAKING SAME
1y 5m to grant Granted Oct 20, 2026
Patent 12757910
Dry-Powdered Cheese Compositions with Naturally-Derived Color Blends, Method of Making and Cheese Product
2y 6m to grant Granted Oct 13, 2026
Patent 12747051
SLICED RARE, MEDIUM RARE AND MEDIUM COOKED ROAST BEEF IN MODIFIED ATMOSPHERE PACKAGING
4y 5m to grant Granted Sep 29, 2026
Patent 12727608
STABLE LIQUID ANIMAL FEED INGREDIENT
3y 8m to grant Granted Sep 08, 2026
Patent 12703842
FUNCTIONAL BEVERAGE CONTAINING 1,3 BUTANEDIOL
2y 6m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
33%
Grant Probability
58%
With Interview (+24.9%)
4y 3m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 871 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month